@article{yeo_ketoacidosis_2019,
	title = {Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: {A} case report},
	volume = {98},
	issn = {0025-7974},
	shorttitle = {Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin},
	url = {http://Insights.ovid.com/crossref?an=00005792-201901180-00067},
	doi = {10.1097/MD.0000000000014150},
	abstract = {Rationale: Dapagliflozin (a sodium-glucose cotransporter-2 [SGLT2] inhibitor) represents the most recently approved class of oral medications for the treatment of type 2 diabetes. Dapagliflozin lowers plasma glucose concentration by inhibiting the renal reuptake of glucose in the proximal renal tubules. In 2015, the US Food and Drug Administration released a warning concerning a potential increased risk of ketoacidosis in patients taking this medication.},
	language = {en},
	number = {3},
	urldate = {2019-06-02},
	journal = {Medicine},
	author = {Yeo, Sang Mok and Park, Hayeon and Paek, Jin Hyuk and Park, Woo Yeong and Han, Seungyeup and Park, Sung Bae and Jin, Kyubok},
	month = jan,
	year = {2019},
	pages = {e14150}
}

{"_id":"hYvser924dzd6JvHw","bibbaseid":"yeo-park-paek-park-han-park-jin-ketoacidosiswitheuglycemiainapatientwithtype2diabetesmellitustakingdapagliflozinacasereport-2019","authorIDs":[],"author_short":["Yeo, S. M.","Park, H.","Paek, J. H.","Park, W. Y.","Han, S.","Park, S. B.","Jin, K."],"bibdata":{"bibtype":"article","type":"article","title":"Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report","volume":"98","issn":"0025-7974","shorttitle":"Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin","url":"http://Insights.ovid.com/crossref?an=00005792-201901180-00067","doi":"10.1097/MD.0000000000014150","abstract":"Rationale: Dapagliflozin (a sodium-glucose cotransporter-2 [SGLT2] inhibitor) represents the most recently approved class of oral medications for the treatment of type 2 diabetes. Dapagliflozin lowers plasma glucose concentration by inhibiting the renal reuptake of glucose in the proximal renal tubules. In 2015, the US Food and Drug Administration released a warning concerning a potential increased risk of ketoacidosis in patients taking this medication.","language":"en","number":"3","urldate":"2019-06-02","journal":"Medicine","author":[{"propositions":[],"lastnames":["Yeo"],"firstnames":["Sang","Mok"],"suffixes":[]},{"propositions":[],"lastnames":["Park"],"firstnames":["Hayeon"],"suffixes":[]},{"propositions":[],"lastnames":["Paek"],"firstnames":["Jin","Hyuk"],"suffixes":[]},{"propositions":[],"lastnames":["Park"],"firstnames":["Woo","Yeong"],"suffixes":[]},{"propositions":[],"lastnames":["Han"],"firstnames":["Seungyeup"],"suffixes":[]},{"propositions":[],"lastnames":["Park"],"firstnames":["Sung","Bae"],"suffixes":[]},{"propositions":[],"lastnames":["Jin"],"firstnames":["Kyubok"],"suffixes":[]}],"month":"January","year":"2019","pages":"e14150","bibtex":"@article{yeo_ketoacidosis_2019,\n\ttitle = {Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: {A} case report},\n\tvolume = {98},\n\tissn = {0025-7974},\n\tshorttitle = {Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin},\n\turl = {http://Insights.ovid.com/crossref?an=00005792-201901180-00067},\n\tdoi = {10.1097/MD.0000000000014150},\n\tabstract = {Rationale: Dapagliflozin (a sodium-glucose cotransporter-2 [SGLT2] inhibitor) represents the most recently approved class of oral medications for the treatment of type 2 diabetes. Dapagliflozin lowers plasma glucose concentration by inhibiting the renal reuptake of glucose in the proximal renal tubules. In 2015, the US Food and Drug Administration released a warning concerning a potential increased risk of ketoacidosis in patients taking this medication.},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2019-06-02},\n\tjournal = {Medicine},\n\tauthor = {Yeo, Sang Mok and Park, Hayeon and Paek, Jin Hyuk and Park, Woo Yeong and Han, Seungyeup and Park, Sung Bae and Jin, Kyubok},\n\tmonth = jan,\n\tyear = {2019},\n\tpages = {e14150}\n}\n\n","author_short":["Yeo, S. M.","Park, H.","Paek, J. H.","Park, W. Y.","Han, S.","Park, S. B.","Jin, K."],"key":"yeo_ketoacidosis_2019","id":"yeo_ketoacidosis_2019","bibbaseid":"yeo-park-paek-park-han-park-jin-ketoacidosiswitheuglycemiainapatientwithtype2diabetesmellitustakingdapagliflozinacasereport-2019","role":"author","urls":{"Paper":"http://Insights.ovid.com/crossref?an=00005792-201901180-00067"},"downloads":0},"bibtype":"article","biburl":"https://bibbase.org/zotero/mydjtl","creationDate":"2019-06-03T05:44:29.039Z","downloads":0,"keywords":[],"search_terms":["ketoacidosis","euglycemia","patient","type","diabetes","mellitus","taking","dapagliflozin","case","report","yeo","park","paek","park","han","park","jin"],"title":"Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report","year":2019,"dataSources":["wgm65LqvnyWA5xx8K"]}